AVXL Anavex Life Sciences Corp
Price (delayed)
$9
Market cap
$765.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
$644.8M
Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease,
Highlights
AVXL's quick ratio is down by 20% YoY but it is up by 6% QoQ
Anavex Life Sciences's equity has decreased by 18% YoY and by 8% QoQ
Anavex Life Sciences's net income has decreased by 8% QoQ and by 8% YoY
Key stats
What are the main financial stats of AVXL
Market
Valuations
Earnings
Shares outstanding
85.06M
Market cap
$765.58M
Enterprise value
$644.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.88
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$55.18M
Net income
-$46.49M
EBIT
-$46.58M
EBITDA
-$46.58M
Free cash flow
-$35.61M
Per share
Balance sheet
Liquidity
EPS
-$0.55
EPS diluted
-$0.55
Free cash flow per share
-$0.42
Book value per share
$1.31
Revenue per share
$0
TBVPS
$1.46
Total assets
$124.04M
Total liabilities
$13.13M
Debt
$0
Equity
$110.92M
Working capital
$110.92M
Debt to equity
0
Current ratio
9.45
Quick ratio
9.2
Net debt/EBITDA
2.59
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.1%
Return on equity
-37.5%
Return on invested capital
N/A
Return on capital employed
-42%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVXL stock price
How has the Anavex Life Sciences stock price performed over time
Intraday
1.12%
1 week
4.77%
1 month
6.26%
1 year
67.29%
YTD
-16.2%
QTD
-16.2%
Financial performance
How have Anavex Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.18M
Net income
-$46.49M
Gross margin
N/A
Net margin
N/A
Anavex Life Sciences's net income has decreased by 8% QoQ and by 8% YoY
AVXL's operating income is down by 7% year-on-year and by 4.3% since the previous quarter
Growth
What is Anavex Life Sciences's growth rate over time
Valuation
What is Anavex Life Sciences stock price valuation
P/E
N/A
P/B
6.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 6% QoQ
The stock's price to book (P/B) is 53% more than its last 4 quarters average of 4.5
Anavex Life Sciences's equity has decreased by 18% YoY and by 8% QoQ
Efficiency
How efficient is Anavex Life Sciences business performance
The ROE has contracted by 24% YoY and by 14% from the previous quarter
AVXL's return on assets is down by 22% year-on-year and by 13% since the previous quarter
Dividends
What is AVXL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVXL.
Financial health
How did Anavex Life Sciences financials performed over time
AVXL's quick ratio is down by 20% YoY but it is up by 6% QoQ
The company's current ratio fell by 20% YoY but it rose by 7% QoQ
The debt is 100% smaller than the equity
Anavex Life Sciences's equity has decreased by 18% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.